Personalized Medicine in the Age of Pharmacoproteomics: A Close up on India and Need for Social Science Engagement for Responsible Innovation in Post-Proteomic Biology.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Metaflammation's Role in Systemic Dysfunction in Obesity: A Comprehensive Review.International journal of molecular sciences · 2025
   Review
2. Personalized Medicine in a New Genomic Era: Ethical and Legal Aspects.Science and engineering ethics · 2017
   Article
3. A Mobilising Concept? Unpacking Academic Representations of Responsible Research and Innovation.Science and engineering ethics · 2017
   Article
4. "Omics"-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives.Proteomes · 2016
   Review
5. Ethical, Political and Societal Implications of the Open Access Journal Movement in the Era of Economic Crisis, with Emphasis on Public Health Pharmacogenomics.Current pharmacogenomics and personalized medicine · 2013
   Article
6. Public Health Pharmacogenomics and the Design Principles for Global Public Goods - Moving Genomics to Responsible Innovation.Current pharmacogenomics and personalized medicine · 2013
   Article
7. End of the Beginning and Public Health Pharmacogenomics: Knowledge in 'Mode 2' and P5 Medicine.Current pharmacogenomics and personalized medicine · 2012
   Article
8. Towards an Ecology of Collective Innovation: Human Variome Project (HVP), Rare Disease Consortium for Autosomal Loci (RaDiCAL) and Data-Enabled Life Sciences Alliance (DELSA).Current pharmacogenomics and personalized medicine · 2011
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

7 authors.

Funding

Abstract

PubMed holds no abstract for this paper.